Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$198 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-1.9 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
11.8
Industry P/E
--
EV/EBITDA
-7.4
Div. Yield
0 %
Debt to Equity
--
Book Value
$0.8
EPS
$-1.2
Face value
--
Shares outstanding
26,491,702
CFO
$--
EBITDA
$--
Net Profit
$--
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Nuvectis Pharma Inc (NVCT)
| 0.1 | -14.7 | 0.1 | -19.1 | -16.8 | -- | -- |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
|---|---|---|---|
|
Nuvectis Pharma Inc (NVCT)
| 39.6 | -34.9 | 11.2 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Nuvectis Pharma Inc (NVCT)
|
7.6 | 198.4 | 0.0 | -26.4 | -- | -188 | -- | 11.8 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 64.5 | 7,360.8 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.3 | 153.4 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 105.4 | 7,603.8 | 0.0 | -425.4 | -- | -36.7 | -- | 6.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug... candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey. Address: 1 Bridge Plaza, Fort Lee, NJ, United States, 07024 Read more
Co-Founder, Chairman, CEO & President
Mr. Ron Bentsur M.B.A.
Co-Founder, Chairman, CEO & President
Mr. Ron Bentsur M.B.A.
Headquarters
Fort Lee, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Nuvectis Pharma Inc (NVCT) is $7.56 (NASDAQ) as of 02-Apr-2026 16:01 EDT. Nuvectis Pharma Inc (NVCT) has given a return of -16.76% in the last 3 years.
Since, TTM earnings of Nuvectis Pharma Inc (NVCT) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-6.28
|
9.02
|
|
2024
|
-4.84
|
9.47
|
|
2023
|
-5.99
|
10.94
|
|
2022
|
-5.19
|
6.86
|
|
2021
|
--
|
--
|
The 52-week high and low of Nuvectis Pharma Inc (NVCT) are Rs 11.52 and Rs 5.55 as of 05-Apr-2026.
Nuvectis Pharma Inc (NVCT) has a market capitalisation of $ 198 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Nuvectis Pharma Inc (NVCT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.04
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.